Mercado de contadores de imunoensaio-gama da América do Norte, por tipo de produto (automatizado, manual/ semiautomático), poço (multipoços, poço único), aplicação (rádio imunoensaios, ensaios de medicina nuclear, outros), condição de doença ( biomarcador de cancro , Doenças infeciosas, monitorização de medicamentos terapêuticos, hormonas endócrinas, alergia, rastreio neonatal, marcadores cardíacos, doenças autoimunes, outros), modo de compra (compra definitiva, compra de aluguer), utilizador final (laboratório, hospitais, institutos académicos e de investigação, farmacêutico e empresas de biotecnologia, bancos de sangue, outros), canal de distribuição (licitação direta, distribuidores de terceiros), país (EUA, Canadá, México) tendências da indústria e previsão para 2028.
Análise de mercado e insights: Mercado de contadores de imunoensaio-gama da América do Norte
O mercado norte-americano de contadores imunoensaios-gama deverá ganhar crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 5,3% no período de previsão de 2021 a 2028 e prevê-se que atinja os 38,85 milhões de dólares até 2028. O aumento da prevalência de doenças crónicas e o aumento da adoção da medicina nuclear são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
Um imunoensaio é um teste bioquímico que mede a presença ou concentração de uma macromolécula ou de uma pequena molécula numa solução através da utilização de um anticorpo ou antigénio. O exame bioquímico é realizado através de um aparelho conhecido por “Contador Gama”. Um contador gama é um instrumento para medir a radiação gama emitida por um radionuclídeo. Ao contrário dos medidores de pesquisa, os contadores gama são concebidos para medir pequenas amostras de material radioativo, normalmente com medição automatizada e movimentação de múltiplas amostras. Espera-se que o aumento dos gastos em investigação e desenvolvimento, o aumento dos gastos em saúde e a sensibilização dos doentes em relação ao tratamento de doenças crónicas proporcionem uma oportunidade de crescimento lucrativa para o mercado. No entanto, o elevado custo dos contadores gama e o risco de radiação gama são os fatores esperados para restringir o crescimento do mercado no período de previsão.
O relatório de mercado de contadores imunoensaio-gama fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receita emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado e dimensão do mercado de contadores de imunoensaio-gama da América do Norte
O mercado de contadores gama de imunoensaio está segmentado com base no tipo de produto, poço, aplicação, condição da doença, modo de compra, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo de produto, o mercado norte-americano de contadores gama de imunoensaio está segmentado em automatizado, manual/semiautomático. Em 2021, prevê-se que o segmento automatizado domine o mercado devido à redução dos custos operacionais e à melhoria da segurança no trabalho.
- Com base no poço, o mercado norte-americano de contadores gama de imunoensaio está segmentado em vários poços e poços únicos. Em 2021, prevê-se que o segmento de múltiplos poços domine o mercado devido às medições precisas e à capacidade de produzir níveis de espectro mais elevados num curto espaço de tempo.
- Com base na aplicação, o mercado norte-americano de contadores gama de imunoensaios está segmentado em radioimunoensaios, ensaios de medicina nuclear, outros. Em 2021, prevê-se que os radioimunoensaios dominem o mercado devido à relativa simplicidade e maior sensibilidade
- Com base na condição da doença, o mercado de contadores gama de imunoensaio da América do Norte está segmentado em biomarcadores de cancro, doenças infeciosas, monitorização de medicamentos terapêuticos, hormonas endócrinas, alergia, rastreio neonatal, marcadores cardíacos, doenças autoimunes, outros. Em 2021, prevê-se que o segmento dos biomarcadores de cancro domine o mercado devido à sua utilização na estimativa do risco de doença e integral ao desenvolvimento de medicamentos.
- Com base no modo de compra, o mercado de contadores gama de imunoensaio da América do Norte está segmentado em compra direta e compra de aluguer. Em 2021, prevê-se que o segmento de compra direta domine o mercado devido ao preço reduzido ou custo total e garanta um maior valor do fornecedor
- Com base no utilizador final, o mercado de contadores gama de imunoensaio da América do Norte está segmentado em laboratórios, hospitais, institutos de investigação e académicos, empresas farmacêuticas e de biotecnologia, bancos de sangue, outros. Em 2021, espera-se que o segmento laboratorial domine o mercado devido à conformidade regulamentar e à redução de custos.
- Com base no canal de distribuição, o mercado norte-americano de contadores de imunoensaio-gama está segmentado em vendas diretas e distribuidores de terceiros. Em 2021, prevê-se que o segmento de licitação direta domine o mercado devido à melhoria da gestão de fornecedores e ao alcance dos custos-alvo.
Análise ao nível do país do mercado de contadores de imunoensaio-gama
O mercado de contadores imunoensaio-gama é analisado e são fornecidas informações sobre o tamanho do mercado com base no tipo de produto, poço, aplicação, condição da doença, modo de compra, utilizador final e canal de distribuição como mencionado acima.
Os países abordados no relatório de mercado Contadores imunoensaios gama são os EUA, o Canadá e o México.
The U.S. is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of accurate measurements, and ability to produce higher spectra levels in short period of time.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Product Approvals and Novelty in Diagnosis Procedures are Boosting the Market Growth of Immunoassay-Gamma Counters
Immunoassay gamma counters market also provides you with detailed market analysis for every country growth in bacteriophage therapy industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Immunoassay-Gamma Counters Market Share Analysis
Immunoassay gamma counters market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to immunoassay-gamma counters market.
The major companies operating in the North America immunoassay-gamma counters market are Hidex Oy, Perkin Elmer Inc, Berthold Technologies GmbH & Co. KG, ENERSYS Co. Ltd, Shinjin Medics Inc, LabLogic Systems Ltd, among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the immunoassay-gamma counters market.
For instance,
- In July 2021, PerkinElmer Inc. announced that the company is further looking to expand their footprints in India by relying on innovative products. The new products will be launched in various streams such as science, pharma, and food testing. This has helped the company to expand its global presence
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the immunoassay-gamma counters market which also provides the benefit for organization to improve their offering for immunoassay-gamma counters.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTES FIVE FORCES
5 REGULATORY GUIDELINES FOR IMMUNOASSAY-GAMMA COUNTERS
5.1 U.S. REGULATORY GUIDELINES FOR IMMUNOASSAYS-GAMMA COUNTERS
5.2 EUROPE REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
5.3 JAPAN REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
5.4 CHINA REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN PREVALENCE OF CHRONIC DISEASES
6.1.2 PRODUCT APPROVAL
6.1.3 INCREASE IN ADOPTION OF NUCLEAR MEDICINE
6.1.4 NOVELTY IN DIAGNOSIS PROCEDURES
6.1.5 UPGRADING GAMMA TECHNOLOGY
6.2 RESTRAINTS
6.2.1 HIGH COST OF GAMMA COUNTER
6.2.2 RISK OF GAMMA RADIATION
6.2.3 STRINGENT REGULATION OF CLINICAL USE OF GAMMA COUNTER
6.2.4 PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 GROWING RESEARCH AND DEVELOPMENT EXPENDITURE
6.3.2 INCREASE IN HEALTHCARE EXPENDITURE
6.3.3 RISE IN PATIENTS AWARENESS TOWARDS CHRONIC DISEASE TREATMENT
6.4 CHALLENGES
6.4.1 CHALLENGES IN USING GAMMA COUNTER
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7 IMPACT OF COVID-19 ON NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET
7.1 IMPACT ON THE PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVES BY MANUFACTURERS
7.5 CONCLUSION
8 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 AUTOMATED
8.2.1 RADIOIMMUNOASSAYS
8.2.1.1 RIA
8.2.1.2 IRMA
8.2.2 NUCLEAR MEDICINE ASSAYS
8.2.2.1 GFR (Glomerular FILTRATION RATE)
8.2.2.2 Gamma glutamyl transferase (ggt)
8.2.2.3 red cell mass and plasma volume test
8.2.2.4 THE SCHILLING TEST
8.2.2.5 others
8.2.3 OTHERS
8.3 MANUAL/SEMI-AUTOMATED
8.3.1 RADIOIMMUNOASSAYS
8.3.1.1 RIA
8.3.1.2 IRMA
8.3.2 NUCLEAR MEDICINE ASSAYS
8.3.2.1 GFR (Glomerular FILTRATION RATE)
8.3.2.2 Gamma glutamyl transferase (ggt)
8.3.2.3 red cell mass and plasma volume test
8.3.2.4 THE SCHILLING TEST
8.3.2.5 others
8.3.3 OTHERS
9 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL
9.1 OVERVIEW
9.2 MULTI-WELL
9.3 SINGLE-WELL
10 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 RADIO IMMUNOASSAYS
10.2.1 RIA
10.2.2 IRMA
10.3 NUCLEAR MEDICINE ASSAY
10.3.1 GFR (GLOMERULAR FILTRATION RATE)
10.3.2 GAMMA-GLUTAMYL TRANSFERASE
10.3.3 RED CELL MASS AND PLASMA VOLUME TEST
10.3.4 THE SCHILLING TEST
10.3.5 OTHERS
10.4 OTHERS
11 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION
11.1 OVERVIEW
11.2 CANCER BIOMARKERS
11.2.1 CARBOHYDRATE ANTIGEN 125 (CA125)
11.2.2 CARBOHYDRATE ANTIGEN 19-9
11.2.3 CARCINO EMBRYONIC ANTIGEN
11.2.4 ALPHA-FETOPROTEIN
11.2.5 OTHERS
11.3 INFECTIOUS DISEASES
11.4 THERAPEUTIC DRUG MONITORING
11.5 ENDOCRINE HORMONES
11.6 ALLERGY
11.7 NEONATAL SCREENING
11.8 CARDIAC MARKERS
11.9 AUTOIMMUNE DISEASE
11.1 OTHERS
12 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE
12.1 OVERVIEW
12.2 OUTRIGHT PURCHASE
12.3 RENTAL PURCHASE
13 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 THIRD PARTY DISTRIBUTORS
14 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 LABORATORY
14.4 BLOOD BANKS
14.5 RESEARCH AND ACADEMIC INSTITUTES
14.6 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
14.7 OTHERS
15 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY GEOGRAPHY
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PERKINELMER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 BRETHOLD TECHNOLOGIES GMBH & CO.KG
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 LABLOGIC SYSTEMS LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 COMPANY SHARE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 SHIN JIN MEDICS INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 HIDEX OY
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 LABORATORY TECHNOLOGIES. INC.
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 ENERSYS, CO.LTD.
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 MIRION TECHNOLOGIES (CAPINTEC),INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABLE 1 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 3 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 4 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 5 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 6 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 7 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 8 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 9 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 10 NORTH AMERICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 12 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 13 NORTH AMERICA MULTI-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 14 NORTH AMERICA SINGLE-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 15 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 16 NORTH AMERICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 17 NORTH AMERICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 18 NORTH AMERICA NUCLEAR MEDICINE ASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 19 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 21 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 22 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 24 NORTH AMERICA INFECTIOUS DISEASES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 25 NORTH AMERICA THERAPEUTIC DRUG MONITORING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ENDOCRINE HORMONES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 27 NORTH AMERICA ALLERGY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 28 NORTH AMERICA NEONATAL SCREENING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 29 NORTH AMERICA CARDIAC MAKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 30 NORTH AMERICA AUTO IMMUNE DISEASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 32 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 33 NORTH AMERICA OUTRIGHT PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 34 NORTH AMERICA RENTAL PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 35 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 36 NORTH AMERICA DIRECT TENDER IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 37 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 38 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 40 NORTH AMERICA LABORATORY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 41 NORTH AMERICA BLOOD BANKS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 20152028 (USD MILLION)
TABLE 42 NORTH AMERICA RESEARCH AND ACADEMIC INSTITUTES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 44 OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 45 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY COUNTRY, 2015-2028 (USD MILLION)
TABLE 46 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 47 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 48 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 49 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 51 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 52 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 53 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 54 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 55 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 56 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 57 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 58 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 59 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 60 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 61 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 62 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 63 U.S. AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 64 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 65 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 66 U.S. MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 67 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 68 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 69 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 70 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 71 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 72 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 73 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 74 U.S. CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 75 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 76 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 77 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 78 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 79 CANADA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 80 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 81 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 82 CANADA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 83 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 84 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 85 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 86 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 87 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 88 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 89 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 90 CANADA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 91 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 92 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 93 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 94 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 95 MEXICO AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 96 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 97 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 98 MEXICO MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 99 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 100 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 101 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 102 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 103 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 104 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 105 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 106 MEXICO CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 107 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 108 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 109 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
Lista de Figura
FIGURE 1 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID
FIGURE 10 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET
FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 16 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020
FIGURE 17 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 19 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020
FIGURE 21 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)
FIGURE 23 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE
FIGURE 24 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020
FIGURE 25 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)
FIGURE 27 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020
FIGURE 29 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)
FIGURE 31 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020
FIGURE 33 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)
FIGURE 35 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020
FIGURE 37 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 39 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020
FIGURE 41 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)
FIGURE 43 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE
FIGURE 44 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SNAPSHOT (2020)
FIGURE 45 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020)
FIGURE 46 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2021 &2028)
FIGURE 47 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 49 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
